Sam-A Pharm삼아제약
009300 · KOSDAQ · ₩009300 · 삼아제약
- Market cap
- ₩87B
- Enterprise value
- ₩11B
- P/E
- 8.3×
- P/B
- 0.4×
- Dividend yield
- 0.0%
- ROE
- 4.6%
- Net margin
- 14.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−20.0% from the high
₩11,950Today: ₩13,340 – ₩13,770₩17,130
Returns
- 1W+0.4%
- 1M−2.4%
- 3M+11.4%
- 6M−16.2%
- YTD−12.8%
- 1Y−18.5%
- Volume today
- 1,854
- 1.7× the 20-day average
- Traded today
- ₩25M
- Listed shares
- 6,370,000
- EPS (12 months)
- ₩1,655
- Earnings yield 12.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 53: heavy trading.
- MomentumFlat-2.4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Sam-A Pharm stock overview
Sam-A Pharm (삼아제약, KRX: 009300) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures and sells pharmaceuticals, including respiratory, dermatological, antipyretic-analgesic-anti-inflammatory, digestive, antibiotic, and circulatory-endocrine products, as well as general medicines and health functional foods. Its shares closed at ₩13,700 on Oct 27, 2026, down 0.44% on the day, giving it a market value of ₩87B.
Key facts
- Market cap
- ₩87B
- Sector
- Biotech & Pharma
- Latest price change
- −0.44%
- As of
- Oct 27, 2026
- Main business
- The company manufactures and sells pharmaceuticals, including respiratory, dermatological, antipyretic-analgesic-anti-inflammatory, digestive, antibiotic, and circulatory-endocrine products, as well as general medicines and health functional foods.
Quick answers about Sam-A Pharm
- What does Sam-A Pharm do?
- The company manufactures and sells pharmaceuticals, including respiratory, dermatological, antipyretic-analgesic-anti-inflammatory, digestive, antibiotic, and circulatory-endocrine products, as well as general medicines and health functional foods. Its main products are prescription drugs, sold to pharmacies and wholesalers through offices in Seoul, the metropolitan area, and other regions, with its main manufacturing plant located in Wonju, Gangwon Province.
- What is the market cap of Sam-A Pharm?
- The market capitalisation of Sam-A Pharm was ₩87B at the close on Oct 27, 2026.
- Who are the largest shareholders of Sam-A Pharm?
- According to the latest official filings, the largest reported holders are Hwang Jong-sook (0.07%, as of Aug 25, 2025).
- When is the next earnings report from Sam-A Pharm?
- Korean companies rarely announce results dates in advance. Based on when Sam-A Pharm filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
The company manufactures and sells pharmaceuticals, including respiratory, dermatological, antipyretic-analgesic-anti-inflammatory, digestive, antibiotic, and circulatory-endocrine products, as well as general medicines and health functional foods. Its main products are prescription drugs, sold to pharmacies and wholesalers through offices in Seoul, the metropolitan area, and other regions, with its main manufacturing plant located in Wonju, Gangwon Province.
Written by AI from the company's latest annual report.
- Korean name
- 삼아제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 허 준
- Founded
- Oct 1973
- Listed
- Jul 2000
- Listed shares
- 6,370,000
- Fiscal year ends
- Month 12
- Website
- www.samapharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Half-year report (Jun 2026)Aug 13, 2026
- Quarterly report (Mar 2026)May 14, 2026
- Amended: Annual report (Dec 2025)Apr 22, 2026
- Amended: Annual general meeting resultsMar 30, 2026
- Corporate value-up planMar 27, 2026
Titles in Korean until English translations are added.
Also known as: Sam-A Pharm / 삼아제약 / 009300 / KRX:009300
Source: KRX statistical information